Department of Genetic Epidemiology, University of Regensburg, Regensburg, Germany.
K. G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology, Trondheim, Norway.
Commun Biol. 2022 Jun 13;5(1):580. doi: 10.1038/s42003-022-03448-z.
Reduced glomerular filtration rate (GFR) can progress to kidney failure. Risk factors include genetics and diabetes mellitus (DM), but little is known about their interaction. We conducted genome-wide association meta-analyses for estimated GFR based on serum creatinine (eGFR), separately for individuals with or without DM (n = 178,691, n = 1,296,113). Our genome-wide searches identified (i) seven eGFR loci with significant DM/noDM-difference, (ii) four additional novel loci with suggestive difference and (iii) 28 further novel loci (including CUBN) by allowing for potential difference. GWAS on eGFR among DM individuals identified 2 known and 27 potentially responsible loci for diabetic kidney disease. Gene prioritization highlighted 18 genes that may inform reno-protective drug development. We highlight the existence of DM-only and noDM-only effects, which can inform about the target group, if respective genes are advanced as drug targets. Largely shared effects suggest that most drug interventions to alter eGFR should be effective in DM and noDM.
肾小球滤过率(GFR)降低可进展为肾衰竭。风险因素包括遗传和糖尿病(DM),但它们的相互作用知之甚少。我们对基于血清肌酐的估算肾小球滤过率(eGFR)进行了全基因组关联荟萃分析,分别针对有或没有 DM 的个体(n=178691,n=1296113)。我们的全基因组搜索确定了(i)7 个具有显著 DM/noDM 差异的 eGFR 位点,(ii)4 个具有提示性差异的额外新位点,(iii)通过允许潜在差异,确定了另外 28 个新的位点(包括 CUBN)。在 DM 个体中进行的 eGFR 全基因组关联研究确定了 2 个已知和 27 个可能导致糖尿病肾病的位点。基因优先级突出了 18 个可能有助于开发肾保护药物的基因。我们强调了 DM 特异性和 noDM 特异性效应的存在,如果将相应的基因作为药物靶点,这可以为目标人群提供信息。大部分共享的效应表明,改变 eGFR 的大多数药物干预措施在 DM 和 noDM 中都应有效。